Psyence Biomedical Ltd.(PBM)Earnings, Financials & Key Ratios

PBM•NASDAQ

$3.11

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryNeuroscience and Psychiatry Therapies

AboutPsyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Show more

Revenue$0
EBITDA-$6M-70.3%
Net Income-$7M-785.6%
EPS (Diluted)0.00-100.0%
ROE-58.62%-489.4%

PBM Price & Volume

Psyence Biomedical Ltd. (PBM) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Burn Threatens Corporate Solvency Stability

Investment Thesis • Updated 2023Q3

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Clinical trial funding exhaustion

Key Thesis Takeaways

Psyence Biomedical operates as a pre-revenue clinical-stage entity, where the absence of commercial sales necessitates a heavy reliance on external capital to fund its PEX010 development pipeline.
The company faces significant execution risks, as evidenced by a $24.8M net loss in 2023Q3 and a precarious liquidity position that leaves little room for operational error.
Investors should monitor the firm's ability to secure non-dilutive funding, as the current trajectory of negative equity and asset erosion suggests a high probability of continued shareholder value impairment.

Verdict Logic

the company's total assets have plummeted from over $250M in 2022Q3 to a mere $1.1K by 2023Q3, indicating an unsustainable path toward clinical milestone achievement.

PBM Growth Metrics

Psyence Biomedical Ltd. (PBM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-421.02%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-827.04%

Return on Capital

10 Years-22.24%

5 Years-22.24%

3 Years-36.52%

Last Year-52.71%

Latest PBM News

Recent stock market news and headlines for Psyence Biomedical Ltd. (PBM)

Business Wire·Jun 16, 2026

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

MINNEAPOLIS--(BUSINESS WIRE)--Tredium Solutions, a provider of pharmacy benefit management (PBM) technologies, has been selected to support the administration of Scripius' commercial, Medicare, and Medicaid pharmacy benefit programs. Through this collaboration, Tredium will provide its claims platform to support accurate and reliable processing for Scripius and the customers it serves. Scripius empowers health plans, health systems, and self-funded employers to better manage rising pharmacy cos.

Peers Comparison

Key metrics vs top competitors for Psyence Biomedical Ltd. (PBM)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
PBMPsyence Biomedical Ltd.Current	$3.11	$41.64M	—	—	—	-58.62%	—
CMPSCOMPASS Pathways plc	$12.99	$1.25B	-4.22	—	—	-151.02%	—
MNMDMind Medicine (MindMed) Inc.	$20.69	$2.04B	-10.04	—	—	-102.48%	—
ATAIAtai Beckley N.V	$5.19	$1.91B	-1.78	1227.6%	-19019.44%	-366.21%	—
CYBNCybin Inc.	$6.09	$303.86M	-13.66	—	—	-81%	—
LSCCLattice Semiconductor Corporation	$130.60	$17.89B	5856.50	2.72%	3.46%	2.79%	—

Compare PBM vs Peers

Psyence Biomedical Ltd. (PBM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CMPS

Most directly comparable listed peer for PBM.

Scale Benchmark

vs LSCC

Larger-name benchmark to compare PBM against a more recognizable public peer.

Peer Set

Compare Top 5

vs CMPS, MNMD, ATAI, CYBN

Get notified when PBM posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

PBM Frequently Asked Questions

Psyence Biomedical Ltd. (PBM) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Is PBM profitable?

Psyence Biomedical Ltd. (PBM) reported a net loss of $25.7M for fiscal year 2025.

Dividend & Returns

What is PBM's return on equity?

Psyence Biomedical Ltd. (PBM) has a return on equity (ROE) of -58.6%. Negative ROE indicates the company is unprofitable.

What is Psyence Biomedical Ltd.'s free cash flow?

Psyence Biomedical Ltd. (PBM) had negative free cash flow of $1.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in PBM back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

PBMPsyence Biomedical Ltd.Current

$3.11

$41.64M

—

-58.62%

—

CMPSCOMPASS Pathways plc

$12.99

$1.25B

-4.22

—

-151.02%

—

MNMDMind Medicine (MindMed) Inc.

$20.69

$2.04B

-10.04

—

-102.48%

—

ATAIAtai Beckley N.V

$5.19

$1.91B

-1.78

1227.6%

-19019.44%

-366.21%

—

CYBNCybin Inc.

$6.09

$303.86M

-13.66

—

-81%

—

LSCCLattice Semiconductor Corporation

$130.60

$17.89B

5856.50

2.72%

3.46%

2.79%

—